FDA finalised its Computer Software Assurance guidance on September 24, 2025, three years after the September 2022 draft first introduced CSA to the pharmaceutical and medical device industry. A further update on February 3, 2026 aligned the guidance with the Quality Management System Regulation and ISO 13485:2016. For anyone responsible for computer system validation, effective CSA training is no longer optional preparation for a future change. It is training for the standard inspectors are applying now.
This guide explains what the final CSA guidance requires, what effective training on the topic should cover and where validation professionals most often misunderstand the framework.
What CSA actually changes
Computer Software Assurance shifts the foundation of validation from documentation volume to critical thinking about patient risk. Under the traditional Computer System Validation approach, every function of every GxP system was typically tested with the same scripted rigour regardless of its actual risk to product quality or patient safety. CSA asks a different question first: what is the intended use of this software, and what is the risk if this specific function fails?
The practical result is that low-risk functions can be verified with unscripted testing, unscripted exploration or by leveraging vendor testing evidence, while high-risk functions - those that directly affect product quality, patient safety or data integrity - still receive rigorous, scripted, evidence-based verification. The total volume of testing decreases. The rigour applied to what actually matters increases.
CSA is fundamentally a critical-thinking framework, not a checklist. This is precisely why CSA training is harder to deliver effectively than traditional CSV training. A validation professional cannot apply CSA correctly by memorising a procedure. They need to genuinely understand how to assess intended use and risk, and that requires training built around real scenarios and judgement, not rote procedure.
What the final guidance requires that the 2022 draft did not fully address
The September 2025 final guidance and February 2026 update added specificity that any current CSA training must cover:
Cloud and SaaS systems are now explicitly defined and addressed. Most GxP software today is cloud-hosted or delivered as SaaS, and the final guidance makes clear these systems fall within CSA scope with no exception, including a detailed worked example involving a SaaS Product Lifecycle Management system and the vendor quality agreements that assurance approach depends on.
AI and machine learning systems are explicitly included in CSA scope in the final guidance. Training that does not address how to apply intended use and risk assessment principles to AI-driven GxP software is missing a requirement that current FDA enforcement - including the April 2026 warning letter citing AI misuse in manufacturing - has already made a live inspection topic.
Cybersecurity evaluation of software vendors is now a formalised expectation, covering vendor development practices, certifications, SOC reports and software bills of materials. This is a genuinely new area of content that most legacy CSV training programmes never covered at all.
Native digital records as assurance evidence are explicitly supported in the final guidance, reducing reliance on manual screenshots and paper printouts that duplicate what a system's own audit trail already captures. Training needs to address when Part 11 controls apply to this data and when they do not.
What effective CSA training needs to cover
Based on the requirements above and the areas where validation teams most often get the practical application wrong, effective CSA training should address the following.
The shift from CSV to CSA in principle, not just procedure
Training needs to explain why the shift happened, not just what changed. Understanding that the industry-wide over-testing under legacy CSV consumed resources without proportionally improving product quality or patient safety is what allows a validation professional to apply CSA judgement correctly to a system or function the training did not specifically cover.
Intended use and risk assessment as the starting point for every system
Every GxP system should begin with a documented intended use assessment. Training should give learners practice actually performing this assessment - not just reading a definition of what it is - because the quality of every downstream assurance decision depends on getting this step right.
Scripted versus unscripted testing - when each applies
A common misunderstanding is that CSA simply replaces scripted testing with unscripted testing across the board. It does not. High-risk functions still require rigorous, often scripted, verification. Training needs to make the distinction concrete with worked examples across different risk levels, not just state the principle abstractly.
Leveraging vendor testing evidence appropriately
CSA explicitly permits leveraging a vendor's own testing evidence to reduce redundant on-site verification for lower-risk functions. Training should cover what makes vendor evidence acceptable to leverage - vendor qualification, evidence quality, and alignment with the specific configuration being used - rather than treating any vendor documentation as automatically sufficient.
GAMP 5 Second Edition alignment
GAMP 5 Second Edition, published in 2022, is explicitly aligned with CSA principles and referenced in FDA's final guidance as recognised industry guidance. Training should show how the GAMP 5 category system and CSA risk-based principles work together in practice, since most validation programmes still use GAMP 5 categorisation as a starting point.
Cloud, SaaS and cybersecurity evaluation
Given how much current GxP software is cloud-delivered, training that treats on-premise, vendor-controlled systems as the default case is out of step with the environment most validation professionals actually work in. Cloud vendor evaluation, quality agreement requirements and cybersecurity assessment need dedicated coverage.
An ISPE survey in early 2024 found that 31% of pharmaceutical professionals had never heard of CSA - a full 21 months after the draft guidance was first published. With the guidance now final and actively shaping inspection expectations, that knowledge gap has become a direct compliance risk rather than a future one.
Who needs CSA training
Validation engineers and computer system validation specialists are the obvious audience, but CSA training has a wider practical reach. IT and system owners who configure and maintain GxP software need to understand how their configuration decisions affect the risk assessment. Quality assurance reviewers who approve validation deliverables need to be able to evaluate whether a CSA-based assurance approach is appropriately justified, not just whether documentation exists. And business process owners who define intended use for a system are making the first and most consequential decision in the entire CSA framework, whether or not they realise it.
GMPify's CSA and GAMP 5 course
GMPify's Computer Software Assurance (CSA) and GAMP 5 course covers the September 2025 final guidance in full, including the February 2026 QMSR update, cloud and SaaS system assurance, AI and machine learning system considerations, cybersecurity evaluation expectations and the practical distinction between scripted and unscripted testing. The course includes a knowledge check and issues a completion certificate, and is included in the GMPify subscription at $69/month alongside 29 additional courses.
Our CSA and GAMP 5 course covers the final guidance in full
FDA CSA final guidance, the February 2026 QMSR update, cloud and SaaS systems, AI system considerations and cybersecurity evaluation. Certificate on completion.